Compare VCRE & DSAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | VCRE | DSAC |
|---|---|---|
| Founded | N/A | 2025 |
| Country | Sweden | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Blank Checks |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 332.9M | 345.6M |
| IPO Year | 2026 | 2025 |
| Metric | VCRE | DSAC |
|---|---|---|
| Price | $11.07 | $10.17 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.7K | ★ 64.5K |
| Earning Date | N/A | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.50 | $9.90 |
| 52 Week High | $13.15 | $10.47 |
| Indicator | VCRE | DSAC |
|---|---|---|
| Relative Strength Index (RSI) | 40.71 | 56.29 |
| Support Level | $10.83 | $9.90 |
| Resistance Level | $13.00 | $10.18 |
| Average True Range (ATR) | 0.73 | 0.00 |
| MACD | -0.09 | -0.00 |
| Stochastic Oscillator | 20.00 | 66.67 |
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
Daedalus Special Acquisition Corp is a blank check company.